STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Results presented at the Annual Meeting of the American Epilepsy Society in Seattle December 6 demonstrate that Retigabine as an adjunctive treatment resulted in statistically significant reduction of seizures and that the response dose-dependent. The study (RESTORE 2) is a randomized, double- blind, placebo-controlled Phase III study (600mg and 900 mg) with the aim to compare Retigabine versus placebo in patients on antiepileptic drug therapy.
